These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29700299)

  • 1. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells.
    Gailhouste L; Liew LC; Hatada I; Nakagama H; Ochiya T
    Cell Death Dis; 2018 May; 9(5):468. PubMed ID: 29700299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells.
    Gailhouste L; Liew LC; Yasukawa K; Hatada I; Tanaka Y; Nakagama H; Ochiya T
    Mol Ther; 2018 Jul; 26(7):1840-1854. PubMed ID: 29759938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma towards a Vitamin D susceptible state.
    He B; Stoffel L; He CJ; Cho K; Li AM; Jiang H; Flowers BM; Nguyen KT; Wang KW; Zhao AY; Zhou MN; Ferreira S; Attardi LD; Ye J
    Cell Death Dis; 2024 Jan; 15(1):89. PubMed ID: 38272889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent.
    Thakar M; Hu Y; Morreale M; Lerner L; Ying Lin W; Sen R; Cai Y; Karunasena E; Thakar M; Saggi S; Keer H; Ahuja N
    PLoS One; 2018; 13(6):e0199130. PubMed ID: 29927979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer.
    Nguyen CDK; Colón-Emeric BA; Murakami S; Shujath MNY; Yi C
    Cell Rep; 2024 May; 43(5):114176. PubMed ID: 38691454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
    Kutschat AP; Hamdan FH; Wang X; Wixom AQ; Najafova Z; Gibhardt CS; Kopp W; Gaedcke J; Ströbel P; Ellenrieder V; Bogeski I; Hessmann E; Johnsen SA
    Cancer Res; 2021 Jun; 81(11):2943-2955. PubMed ID: 33436389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
    Eyres M; Lanfredini S; Xu H; Burns A; Blake A; Willenbrock F; Goldin R; Hughes D; Hughes S; Thapa A; Vavoulis D; Hubert A; D'Costa Z; Sabbagh A; Abraham AG; Blancher C; Jones S; Verrill C; Silva M; Soonawalla Z; Maughan T; Schuh A; Mukherjee S; O'Neill E
    Gastroenterology; 2021 Aug; 161(2):653-668.e16. PubMed ID: 33915173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma.
    Ebelt ND; Zuniga E; Johnson BL; Diamond DJ; Manuel ER
    Front Immunol; 2020; 11():538. PubMed ID: 32296439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity.
    Khoshchehreh R; Totonchi M; Carlos Ramirez J; Torres R; Baharvand H; Aicher A; Ebrahimi M; Heeschen C
    Oncogene; 2019 Aug; 38(34):6226-6239. PubMed ID: 31308488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
    Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
    Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
    Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma.
    Li F; Si W; Xia L; Yin D; Wei T; Tao M; Cui X; Yang J; Hong T; Wei R
    Mol Cancer; 2024 May; 23(1):90. PubMed ID: 38711083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
    Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
    J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.